AMAP102 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetics Study in Healthy Subjects.

Trial Profile

AMAP102 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetics Study in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs AMAP 102 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 01 Jun 2010 Positive results reported in an AnaMar media release.
    • 01 Jun 2010 Status changed from discontinued to completed according to an AnaMar media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top